These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35284125)
1. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer. Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125 [TBL] [Abstract][Full Text] [Related]
2. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy. Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114 [TBL] [Abstract][Full Text] [Related]
3. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085 [TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721 [TBL] [Abstract][Full Text] [Related]
5. Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection. Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK J Gastrointest Oncol; 2022 Jun; 13(3):1402-1412. PubMed ID: 35837183 [TBL] [Abstract][Full Text] [Related]
6. Impact of somatic mutations on clinical and pathologic outcomes in borderline resectable and locally advanced pancreatic cancer treated with neoadjuvant chemotherapy and stereotactic body radiotherapy followed by surgical resection. Reddy AV; Hill CS; Sehgal S; Ding D; Hacker-Prietz A; He J; Zheng L; Herman JM; Meyer J; Narang AK Radiat Oncol J; 2021 Dec; 39(4):304-314. PubMed ID: 34986552 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768 [TBL] [Abstract][Full Text] [Related]
8. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Alagappan M; Pollom EL; von Eyben R; Kozak MM; Aggarwal S; Poultsides GA; Koong AC; Chang DT Am J Clin Oncol; 2018 Mar; 41(3):242-247. PubMed ID: 26757436 [TBL] [Abstract][Full Text] [Related]
9. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157 [TBL] [Abstract][Full Text] [Related]
10. Vertebral body and splenic irradiation are associated with lymphopenia in localized pancreatic cancer treated with stereotactic body radiation therapy. Reddy AV; Deek MP; Jackson JF; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK Radiat Oncol; 2021 Dec; 16(1):242. PubMed ID: 34952610 [TBL] [Abstract][Full Text] [Related]
11. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Ryan JF; Groot VP; Rosati LM; Hacker-Prietz A; Narang AK; McNutt TR; Jackson JF; Le DT; Jaffee EM; Zheng L; Laheru DA; He J; Pawlik TM; Weiss MJ; Wolfgang CL; Herman JM Ann Surg Oncol; 2018 Jan; 25(1):280-289. PubMed ID: 29063299 [TBL] [Abstract][Full Text] [Related]
12. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy. Park Y; Chang AR Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581 [TBL] [Abstract][Full Text] [Related]
14. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy. Xia WY; Zhu XR; Feng W; Liu J; Wang JM; Lv CX; Zhang Q; Yu W; Cai XW; Fu XL Transl Lung Cancer Res; 2020 Oct; 9(5):1996-2007. PubMed ID: 33209619 [TBL] [Abstract][Full Text] [Related]
15. Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy. Zhuang Y; Yuan BY; Hu Y; Chen GW; Zhang L; Zhao XM; Chen YX; Zeng ZC Cancer Manag Res; 2019; 11():10929-10937. PubMed ID: 32099457 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study. Piao MN; Xie J; Jin MM; Ma XT; Dou Z; Wang JP; Li JL Transl Lung Cancer Res; 2024 Aug; 13(8):1950-1963. PubMed ID: 39263027 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. Sutera PA; Bernard ME; Wang H; Heron DE Front Oncol; 2018; 8():282. PubMed ID: 30101127 [No Abstract] [Full Text] [Related]
18. Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. Jung JH; Song C; Jung IH; Ahn J; Kim B; Jung K; Lee JC; Kim J; Hwang JH Front Oncol; 2022; 12():1050070. PubMed ID: 36620548 [TBL] [Abstract][Full Text] [Related]
19. Upfront Chemotherapy Followed by Stereotactic Body Radiation Therapy with or without Surgery in Older Patients with Localized Pancreatic Cancer: A Single Institution Experience and Review of the Literature. Reddy AV; Sehgal S; Hill CS; Zheng L; He J; Herman JM; Meyer J; Narang AK Curr Oncol; 2022 Jan; 29(1):308-320. PubMed ID: 35049702 [TBL] [Abstract][Full Text] [Related]
20. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Wolfe AR; Siedow M; Nalin A; DiCostanzo D; Miller ED; Diaz DA; Arnett A; Cloyd JM; Dillhoff M; Ejaz A; Tsung A; Williams TM Radiother Oncol; 2021 May; 158():207-214. PubMed ID: 33667588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]